Molecular characterization of cancers with ALK gene fusions in nonlung tumors.

• DOI: 10.1200/jco.2022.40.16_suppl.3121
• Publication Date: 2022-06-06T16:09:21Z
• Authors: Jin Zhang; Yushuai Han; Weiran Wang; Mengxiang Xu; Jianhua Zhu; Tonghui Ma
• Keywords: 03 medical and health sciences; 0302 clinical medicine; 3. Good health

3121 Background: ALK gene rearrangement is known as “diamond mutation”. Targeted tyrosine kinase inhibitors have perfect therapeutic effects on fusion lung cancer patients (pts), but the molecular characteristics of fusions in other cancers not been systematically elucidated. Methods: We retrospectively analyzed NGS data fusion-positive Chinese tumor pts (n = 1068) to characterize pan-cancer (excluding cancer) pts. Results: A total 66 with 13 types were screened, including 0.4% (24/5800) brain pts, 0.1% (11/7725) gastrointestinal (7/1741) thyroid 0.5% (8/1732) sarcoma 0.2% (4/2031) liver 0.6% (3/540) melanoma 9% (2/22) inflammatory myofibroblastic 2.5% (2/79) embryonal (1/282) lymphoma 3.2% (1/31) parotid carcinoma (1/985) breast (1/241) prostatic and 0.3% (1/320) ovarian Herein, we reported 28 patterns, which most common partners EML4 24) STRN 8), mainly occurred tumors (14/24, 58.8%) (6/8, 75%), respectively. In addition, there 8 modes that never before. Of patterns described above, 92.4% (61/66) located at canonical site (exon20), preserving intact domain. Meanwhile, rare positions also found, such PPP1CB-ALK(ex2:ex4), NUP107-ALK(ex20:ex3), COL14A1-ALK(ex8:ex4), BRAF-ALK(ex9:ex4), preserve extracellular transmembrane domains, well RASD2-ALK(ex2:ex24), breakpoint may disrupt formation Conclusions: demonstrated rarity nonlung cancers. Analyzing these help clarify their pathogenesis provide ideas for new drug treatment.[Table: see text]